Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.
about
The path for metal complexes to a DNA targetHydrogen bonding and anticancer properties of water-soluble chiral p-cymene Ru(II) compounds with amino-oxime ligandsSynthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexesIn vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancerInduced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centersDNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(ii) terpyridine complexes.Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells.Unusual DNA binding modes for metal anticancer complexes.Ruthenium-based chemotherapeutics: are they ready for prime time?Preparation of organometallic ruthenium-arene-diaminotriazine complexes as binding agents to DNA.Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.Half-sandwich ruthenium–arene complexes with thiosemicarbazones: synthesis and biological evaluation of [(η⁶-p-cymene)Ru(piperonal thiosemicarbazones)Cl]Cl complexesTransfer hydrogenation catalysis in cells as a new approach to anticancer drug design.Inhibition of cancer cell growth by ruthenium complexesMetal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cellsFighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies.Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.Tuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium's success?Metal complex interactions with DNA.DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity.Identification and discrimination of binding sites of an organoruthenium anticancer complex to single-stranded oligonucleotides by mass spectrometry.Competitive binding sites of a ruthenium arene anticancer complex on oligonucleotides studied by mass spectrometry: ladder-sequencing versus top-down.Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes.Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexesExploring the Influence of the Aromaticity on the Anticancer and Antivascular Activities of Organoplatinum(II) Complexes.Combining a Ru(ii)-arene complex with a NO-releasing nitrate-ester ligand generates cytotoxic activity.Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells.Comparison between polypyridyl and cyclometalated ruthenium(II) complexes: anticancer activities against 2D and 3D cancer models.A comparative DFT study on aquation and nucleobase binding of ruthenium (II) and osmium (II) arene complexes.Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies."Head-to-head" double-hamburger-like structure of di-ruthenated d(GpG) adducts of mono-functional Ru-arene anticancer complexes.Factors that influence the antiproliferative activity of half sandwich Ru(II)-[9]aneS3 coordination compounds: activation kinetics and interaction with guanine derivatives.New half sandwich Ru(II) coordination compounds for anticancer activity.The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity.Synthesis and in vitro anticancer activity of ruthenium-cymene complexes with cyclohexyl-functionalized ethylenediamine-N,N'-diacetate-type ligands.The antimicrobial activity of inert oligonuclear polypyridylruthenium(II) complexes against pathogenic bacteria, including MRSA.A mechanistic approach for the DNA binding of chiral enantiomeric L- and D-tryptophan-derived metal complexes of 1,2-DACH: cleavage and antitumor activity.Arene ruthenium complexes as anticancer agents.
P2860
Q26999667-1CEC8660-D4CC-42F9-9163-7AE508798CBBQ28834484-EA8F04BB-7DA4-4982-8408-19AA98A05550Q30358389-D1657995-FA52-4A4F-91B0-8B0174F56391Q30398565-FD556140-607F-4028-8B20-818C0ABC73BDQ30885519-ED844864-5148-4DD7-8AD7-5127307987A5Q31043552-DD1A5274-8770-44BC-9633-901A5317F1BFQ34020456-D1F5A6EC-54FC-489F-8826-D454FF76304CQ34071185-C1AEC9D4-5702-4DFC-8B4E-EB103F90FFBCQ34102818-7915F9FB-E99B-466B-80B4-345B38778289Q34151556-BBE5171D-7B3F-45B6-9A16-715E233E8F1BQ34234520-89E15A38-1A15-42D3-9B20-DA2508EED91CQ35034267-25710217-C145-41D8-B433-0294B8404E7EQ35247064-8BCAE289-C099-4B36-8FEA-D6753410039FQ36574799-327F732D-F8EF-4C31-A2FE-4E677CFF8A30Q37198743-F6255D76-7485-47E1-AF3E-77DCCAE672C1Q37337277-9881E22C-4CFC-459B-8817-22EC7E90B317Q37603642-37A91B54-F51E-480A-8356-85687E896B9BQ37855894-3C5560B1-25C4-4409-BA61-BEEDDDACE5B8Q38271731-FAAA03E3-3155-4FD2-8BF3-A8F6AA09B0E5Q38287806-BB0C4CF6-85DC-4C6C-98F9-A9D4269CD174Q38305756-9C96E3B1-853D-40C0-B93C-3CFE497DB40BQ38317740-0C18530A-319D-4397-A007-BD33D7B1EEE2Q38320711-D4681D95-0BDE-4B4E-94A3-3A61E7EAC9B7Q38328481-A3AF7578-ADBE-481D-9F27-CAE6A1223BD8Q38693266-1E01F02D-0279-48C1-8D7C-652BD3C07E5DQ38712938-4FEFB5F7-2941-4406-A59C-20FE9F4E8317Q38734166-DEA35C2D-CCFD-4D7B-869C-043847B21595Q38829629-8CB82CB5-6DC5-4F39-8096-68C69788718CQ38941173-067CAAC5-56F5-4DF6-A516-B79A9545A1CFQ39095894-30CB212A-8693-4A7D-B0E7-E200F692A9F5Q39121561-661354E4-E6C5-4355-8CE0-C16F5D0C67A8Q39199644-C0368931-D2A9-401F-978F-16A32390D943Q39295123-7CFCB4DE-347B-46B0-A370-20B21C547911Q39349142-53678C21-517A-484C-B934-D204D5DADE30Q39400527-D89F9C46-C5EE-4C88-AC18-114AB1F250EDQ39488143-CBEEF0C0-512D-48A8-AEDD-48363B3BCE5DQ39497208-84E4622E-5840-4E9E-BA73-D2201E627053Q39569670-1C0DC8A8-0F98-4141-93EC-4BBFE8FEDA09Q39647326-04575AA6-BBA6-495A-A540-F21965569284Q39706669-41A8F9D7-610C-4DA7-958A-EFCA330F2F26
P2860
Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Highly selective binding of or ...... novel recognition mechanisms.
@ast
Highly selective binding of or ...... novel recognition mechanisms.
@en
Highly selective binding of or ...... novel recognition mechanisms.
@nl
type
label
Highly selective binding of or ...... novel recognition mechanisms.
@ast
Highly selective binding of or ...... novel recognition mechanisms.
@en
Highly selective binding of or ...... novel recognition mechanisms.
@nl
prefLabel
Highly selective binding of or ...... novel recognition mechanisms.
@ast
Highly selective binding of or ...... novel recognition mechanisms.
@en
Highly selective binding of or ...... novel recognition mechanisms.
@nl
P2093
P356
P1476
Highly selective binding of or ...... novel recognition mechanisms.
@en
P2093
Haimei Chen
John A Parkinson
Peter J Sadler
Robert E Morris
P304
P356
10.1021/JA027719M
P407
P577
2003-01-01T00:00:00Z